Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Clindamycin Action Pathway
Homo sapiens
Drug Action Pathway
Created: 2013-08-22
Last Updated: 2019-08-16
Clindamycin is a natural antibiotic that produced by Streptomyces lincolnensis, which can be used for treating various bacterial infections by binding and inhibiting 23S portion of 50S subunit of ribosomes. Blocking the portion of ribosome can prevent transpeptidase reaction that will elongate peptide chain. Clindamycin has a bacteriostatic effect. It is used primarily to treat infections caused by susceptible anaerobic bacteria, including infections of the respiratory tract, skin and soft tissue infections, and peritonitis. In patients with hypersensitivity to penicillins, clindamycin may be used to treat infections caused by susceptible aerobic bacteria as well. Clindamycin may also be used in combination with chloroquine and quinine to treat malaria caused by Pasmodium falciparum. It is commonly used as a topical treatment for acne, and can be useful against some methicillin-resistant Staphylococcus aureus (MRSA) infections. Clindamycin may also be used to treat bone and joint infections, particularly those caused by Staphylococcus aureu
References
Clindamycin Pathway References
Dalacin C. (2009). e-CPS (online version of Compendium of Pharmaceuticals and Specialties). Retrieved July 17, 2009.
Song, K.S. Ribosomal protein synthesis inhibitors. In S. Offermanns, & W. Rosenthal (Eds.). Encyclopedic reference of molecular pharmacology. (2004) p. 827-833. Berlin, Germany: Springer.
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
No Proteins Present
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
No Proteins Present
Settings